One in ten Americans suffers from a rare disease, often enduring long diagnostic journeys, averaging five or more years for an accurate diagnosis. Healthcare advancement necessitates translating scientific research into tangible patient impact, shortening the time to diagnosis. Whole genome sequencing (WGS) is emerging as a crucial tool, recommended by professional societies for various clinical indications and seen as a potential first-line diagnostic. While WGS coverage is increasing across commercial and Medicaid plans, challenges remain in accelerating access, clinical implementation, and expanding guidelines. WGS offers the highest diagnostic yield compared to other genetic tests, analyzing up to 98% of the genome and providing deeper insights for accurate diagnoses. However, WGS alone cannot diagnose every patient due to biological and technical limitations, leaving a persistent diagnostic gap. Closing this gap requires a comprehensive approach, starting with WGS as a foundation and selectively incorporating complementary technologies like RNA sequencing or optical genome mapping. This multimodal strategy allows for a more precise view of the genome, addressing complex cases and bringing clarity to patients. Furthermore, reanalysis of WGS data years later can uncover new gene-disease associations or identify candidates for newer complementary technologies. The future of rare disease diagnostics lies in effectively integrating multiple technologies to improve patient care and outcomes. Moving beyond a single technology and embracing an integrated, multimodal approach is essential to close the diagnostic gap and provide meaningful care.